Want to join the conversation?
In 3Q15, $VRTX's non-GAAP R&D and SG&A expenses were $278MM, an increase of $66MM compared to last year. This increase is mainly attributable to an increase in sales and marketing expenses supporting the launch of ORKAMBI. $VRTX expects modest increases in OpEx in 2016.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.